Bio-Techne Corporation (TECH) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
TECH price how computed
Forward Fair Value verdict
UndervaluedTECH is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $72.46
- Sector
- Healthcare
- 12-month range
- $43.30–$72.61
- Market cap
- $11.4B
- From 52-week high
- -0.2%
- Shares outstanding
- 157M
- Rank in Healthcare by discount to fair value
- #42 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Bio-Techne Corporation is a life sciences company that develops and manufactures proteins, antibodies, and other reagents used in research and diagnostics. The company operates globally, serving customers in academic institutions, pharmaceutical and biotechnology companies, and clinical diagnostic laboratories across North America, Europe, and Asia.
TECH currently ranks #42 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $11.4B
- P/E (trailing)
- 39x
- Revenue (TTM)
- $1.22B
- Net margin
- 15.0%
- EPS (TTM)
- $1.84
- Gross margin
- 65.8%
- Debt / equity
- 0.14
- Revenue growth (3-yr avg)
- 5.3%
- Shares outstanding
- 157M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 56 · neutral
- 50-day average
- $72.38
- 200-day average
- $62.74
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $0.32 per share (4 payments)
- Yield on last price
- 0.44%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-08-24
- Last payment date
- 2026-09-04
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 6 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.5%)
2026-03 ▬ met (0.0%)
2025-12 ▲ beat (+7.0%)
2025-09 ▬ met (0.0%)
2025-06 ▲ beat (+6.0%)
2025-03 ▲ beat (+9.8%)
2024-12 ▲ beat (+7.7%)
2024-09 ▲ beat (+10.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 12 hold · 0 sell (13 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $70.5
- Target vs last price
- -2.7%
What our data shows for TECH
- Our model validated 17 trailing price-to-earnings windows for TECH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $43.30–$72.61.
- The 14-day relative strength index sits at a neutral 56.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TECH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TECH news
TickrTrends' derived news-sentiment signal for TECH is currently leaning positive, computed from recent coverage.
- Bio-Techne (TECH) Shareholders Approve $Merger Agreement With Merck KGaA (gurufocus.com, 2026-09-24)
TickrTrends take: Shareholders of Bio-Techne have approved a merger agreement with Merck KGaA, which represents a significant corporate event that could affect the company's valuation trajectory. Given TickrTrends' current assessment that TECH is undervalued, investors focused on valuation metrics should monitor how this transaction impacts the company's future earnings power and whether the merger price aligns with or diverges from intrinsic value estimates. The consolidation within the healthcare sector could also influence comparable company multiples and industry dynamics that factor into valuation reassessment. - TECH Looks 1.7% Overvalued on GF Value™ (gurufocus.com, 2026-09-23)
TickrTrends take: TECH is showing a valuation divergence, with the GF Value metric indicating a modest overvaluation while TickrTrends currently assesses the stock as undervalued. This disconnect between valuation methodologies highlights the importance of monitoring how consensus views may shift as new data emerges. Investors focused on valuation metrics should track whether TECH's fundamentals in the Healthcare sector evolve to close the gap between these different assessment approaches. - TECH Looks 1.7% Overvalued on GF Value™ (gurufocus.com, 2026-09-23)
TickrTrends take: # TECH Valuation Analysis TECH is currently assessed as undervalued by TickrTrends, which creates a notable divergence from the GF Value model's assessment of overvaluation. A valuation-focused reader should monitor whether this gap narrows or widens, as it may indicate either a timing opportunity or a sign that one of the models requires recalibration based on the company's healthcare sector fundamentals. The tension between these two valuations suggests investors should examine the underlying assumptions driving each assessment before making decisions.
What people are saying
Follow the TECH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — TickrTrends' derived indicators for TECH in the Healthcare sector reflect a shift in relative valuation positioning this week. The sector discount rank moved from 50 to 57, indicating the sector has moved lower in the ranking of discounted valuations across comparable peers. Despite this decline in rank, the current valuation verdict remains Undervalued.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TECH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), TECH is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is TECH's TickrTrends verdict?
TECH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does TECH compare to other Healthcare stocks?
TECH ranks #42 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is TECH overbought or oversold?
TECH's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does TECH pay a dividend?
Yes. TECH paid $0.32 per share over the last twelve months (4 payments), a 0.44% yield on TickrTrends' last price. The last ex-dividend date was 2026-08-24.
When does TECH report earnings next?
TECH's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does TECH usually beat earnings estimates?
Over its last 8 reported quarters TECH beat the consensus estimate 6 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TECH?
Of 13 analysts covering TECH, 1 rate it a buy, 12 a hold and 0 a sell - hold-leaning, with a consensus price target of $70.5 (-2.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
TECH vs ALNY · TECH vs BAX · TECH vs BDX · TECH vs ENSG · TECH vs HSIC